Page 44 - 2018_11-Haematologica-web

J. Caers et al.
Blood. 2015;126(23):191-191.
92. Zamagni E, Nanni C, Mancuso K, et al. PET/CT improves the definition of com- plete response and allows to detect other- wise unidentifiable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21(19):4384-4390.
93. Dawson S-J, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to mon- itor metastatic breast cancer. N Engl J Med. 2013;368(13):1199-1209.
94. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-990.
95. Oberle A, Brandt A, Voigtlaender M, et al. Monitoring multiple myeloma by next-gen- eration sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. Haematologica. 2017;102 (6):1105-1111.
96. Mithraprabhu S, Khong T, Ramachandran M, et al. Circulating tumour DNA analysis demonstrates spatial mutational heterogene- ity that coincides with disease relapse in myeloma. Leukemia. 2017;31(8):1695-1705.
97. Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexametha- sone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood. 2015;125(9):1411-1417.
98. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multi- ple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109(8):3489-3495.
99. An G, Acharya C, Deng S, et al. Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. Exp Hematol. 2015;43(3):168- 176.e162.
100.Klein U, Jauch A, Hielscher T, et al. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. Cancer. 2011;117(10):2136-2144.
101.Nahi H, Våtsveen TK, Lund J, et al.
Proteasome inhibitors and IMiDs can over- come some high-risk cytogenetics in multi- ple myeloma but not gain 1q21. Eur J Haematol. 2016;96(1):46-54.
102. Hebraud B, Leleu X, Lauwers-Cances V, et al. Deletion of the 1p32 region is a major inde- pendent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia. 2014;28(3):675-679.
103.Lakshman A, Moustafa MA, Rajkumar SV, et al. Natural history of t(11;14) multiple myeloma. Leukemia. 2018;32(1):131-138.
104. Avet-Loiseau H, Malard F, Campion L, et al. Translocation t(14;16) and multiple myelo- ma: is it really an independent prognostic factor? Blood. 2011;117(6):2009-2011.
105. Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials. J Clin Oncol. 2017;35(25): 2900-2910.
106. Chakraborty R, Muchtar E, Kumar SK, et al. Impact of post-transplant response and min- imal residual disease on survival in myeloma with high-risk cytogenetics. Biol Blood Marrow Transplant. 2017;23(4):598-605.
107. Nadiminti K, Singh Abbi KK, Mott SL, et al. VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD- negative status in multiple myeloma. Onco Targets Ther. 2017;10:217-226.
108. Paiva B, Cedena M-T, Puig N, et al. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. Blood. 2016;127(25):3165-3174.
109. Ludwig H, Greil R, Masszi T, et al. Bortezomib, thalidomide and dexametha- sone, with or without cyclophosphamide, for patients with previously untreated mul- tiple myeloma: 5-year follow-up. Br J Haematol. 2015;171(3):344-354.
110.Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexam- ethasone combination as induction and con- solidation followed by lenalidomide mainte- nance in patients with multiple myeloma: a
phase II study by the Intergroupe Francophone du Myélome. J Clin Oncol. 2014;32(25):2712-2717.
111. Mateos M-V, Oriol A, Martínez-López J, et al. GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkyla- tors? Blood. 2014;124(12):1887-1893.
112. Oliva S, Gambella M, Gilestro M, et al. Minimal residual disease after transplanta- tion or lenalidomide-based consolidation in myeloma patients: a prospective analysis. Oncotarget. 2017;8(4):5924-5935.
113. Puig N, Sarasquete ME, Balanzategui A, et al. Critical evaluation of ASO RQ-PCR for min- imal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia. 2014;28(2):391-397.
114. Ferrero S, Ladetto M, Drandi D, et al. Long- term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on sur- vival. Leukemia. 2015;29(3):689-695.
115.Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dex- amethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974- 981.
116. Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide- dexamethasone with lenalidomide exten- sion in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015;1(6):746-754.
117.Patriarca F, Carobolante F, Zamagni E, et al. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evalua- tion of patients with multiple myeloma undergoing allogeneic stem cell transplanta- tion. Biol Blood Marrow Transplant. 2015;21(6):1068-1073.
118.Lapa C, Luckerath K, Malzahn U, et al. 18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantation. Oncotarget. 2014;5(17):7381-7391.
1784
haematologica | 2018; 103(11)